{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T17:58:49Z","timestamp":1712771929799},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,16]]},"DOI":"10.7759\/cureus.48898","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T16:15:16Z","timestamp":1700151316000},"source":"Crossref","is-referenced-by-count":1,"title":["Ceftriaxone-Induced Thrombotic Thrombocytopenic Purpura Treated Successfully With Plasmapheresis and Eculizumab: A Rare Case Report"],"prefix":"10.7759","author":[{"given":"Zaheer A","family":"Qureshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faryal","family":"Altaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikail","family":"Khanzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Thet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George JN","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014, 371:654-66. 10.1056\/NEJMra1312353","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng XL","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR, et al.. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020, 18:2496-502. 10.1111\/jth.15010","journal-title":"J Thromb Haemost"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients","volume":"325","author":"Bell WR","year":"1991","unstructured":"Bell WR, Braine HG, Ness PM, Kickler TS. Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med. 1991, 325:398-403. 10.1056\/NEJM199108083250605","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14804","article-title":"ADAMTS13: origins, applications, and prospects","volume":"58","author":"Plautz WE","year":"2018","unstructured":"Plautz WE, Raval JS, Dyer MR, Rollins-Raval MA, Zuckerbraun BS, Neal MD. ADAMTS13: origins, applications, and prospects. Transfusion. 2018, 58:2453-62. 10.1111\/trf.14804","journal-title":"Transfusion"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-200109000-00004","article-title":"Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome","volume":"8","author":"Medina PJ","year":"2001","unstructured":"Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001, 8:286-93. 10.1097\/00062752-200109000-00004","journal-title":"Curr Opin Hematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21420","article-title":"Thrombotic thrombocytopenic purpura in a postoperative patient taking cephalexin responding to plasmapheresis: A case report and review of cephalosporin-induced TTP","volume":"31","author":"Patel R","year":"2016","unstructured":"Patel R, Amber KT. Thrombotic thrombocytopenic purpura in a postoperative patient taking cephalexin responding to plasmapheresis: A case report and review of cephalosporin-induced TTP. J Clin Apher. 2016, 31:473-5. 10.1002\/jca.21420","journal-title":"J Clin Apher"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-011-9794-9","article-title":"Thrombotic thrombocytopenic purpura after prophylactic cefuroxime axetil administered in relation to a liposuction procedure","volume":"36","author":"Eskazan AE","year":"2012","unstructured":"Eskazan AE, Salihoglu A, Gulturk E, Ongoren S, Soysal T. Thrombotic thrombocytopenic purpura after prophylactic cefuroxime axetil administered in relation to a liposuction procedure. Aesthetic Plast Surg. 2012, 36:464-7. 10.1007\/s00266-011-9794-9","journal-title":"Aesthetic Plast Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003595.pub2","article-title":"Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura","volume":"2009","author":"Michael M","year":"2009","unstructured":"Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev. 2009, 2009:CD003595. 10.1002\/14651858.CD003595.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Kremer Hovinga JA","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, L\u00e4mmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017, 3:17020. 10.1038\/nrdp.2017.20","journal-title":"Nat Rev Dis Primers"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25689","article-title":"Furosemide-induced thrombotic thrombocytopenic purpura: a report of a rare case","volume":"14","author":"Chandok T","year":"2022","unstructured":"Chandok T, Qureshi ZA, Yapor L, Khaja M. Furosemide-induced thrombotic thrombocytopenic purpura: a report of a rare case. Cureus. 2022, 14:e25689. 10.7759\/cureus.25689","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23525","article-title":"Mitomycin-induced thrombotic thrombocytopenic purpura treated successfully with plasmapheresis and steroid: a case report","volume":"14","author":"Khaja M","year":"2022","unstructured":"Khaja M, Qureshi ZA, Kandhi S, Altaf F, Yapor L. Mitomycin-induced thrombotic thrombocytopenic purpura treated successfully with plasmapheresis and steroid: a case report. Cureus. 2022, 14:e23525. 10.7759\/cureus.23525","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi F","year":"2016","unstructured":"Peyvandi F, Scully M, Kremer Hovinga JA, et al.. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016, 374:511-22. 10.1056\/NEJMoa1505533","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.57.061804.084505","article-title":"Current concepts in thrombotic thrombocytopenic purpura","volume":"57","author":"Tsai HM","year":"2006","unstructured":"Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med. 2006, 57:419-36. 10.1146\/annurev.med.57.061804.084505","journal-title":"Annu Rev Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli T","year":"2022","unstructured":"Mazzierli T, Allegretta F, Maffini E, Allinovi M. Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management. Front Pharmacol. 2022, 13:1088031. 10.3389\/fphar.2022.1088031","journal-title":"Front Pharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/143832","article-title":"Ciprofloxacin-induced thrombotic thrombocytopenic purpura: a case of successful treatment and review of the literature","volume":"2015","author":"Hashmi HR","year":"2015","unstructured":"Hashmi HR, Diaz-Fuentes G, Jadhav P, Khaja M. Ciprofloxacin-induced thrombotic thrombocytopenic purpura: a case of successful treatment and review of the literature. Case Rep Crit Care. 2015, 2015:143832. 10.1155\/2015\/143832","journal-title":"Case Rep Crit Care"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx081","article-title":"Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea","volume":"10","author":"Brocklebank V","year":"2017","unstructured":"Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J. 2017, 10:600-24. 10.1093\/ckj\/sfx081","journal-title":"Clin Kidney J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2018.03.005","article-title":"Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies","volume":"57","author":"Vigna E","year":"2018","unstructured":"Vigna E, Petrungaro A, Perri A, et al.. Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies. Transfus Apher Sci. 2018, 57:247-9. 10.1016\/j.transci.2018.03.005","journal-title":"Transfus Apher Sci"},{"key":"ref18","article-title":"Thrombotic thrombocytopenic purpura","author":"Stanley M","year":"2023","unstructured":"Stanley M, Killeen RB, Michalski JM. Thrombotic thrombocytopenic purpura. Stanley M, Killeen RB, Michalski JM (ed): StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref19","article-title":"Thrombotic thrombocytopenic purpura associated with clopidogrel: a case report and review of the literature","volume":"16","author":"Azarm T","year":"2011","unstructured":"Azarm T, Sohrabi A, Mohajer H, Azarm A. Thrombotic thrombocytopenic purpura associated with clopidogrel: a case report and review of the literature. J Res Med Sci. 2011, 16:353-7.","journal-title":"J Res Med Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27104","article-title":"Drug-induced thrombotic microangiopathy and thrombotic thrombocytopenic purpura: a systematic review, 2018-2023","author":"Khan S","year":"2023","unstructured":"Khan S, George JN, Nusrat S. Drug-induced thrombotic microangiopathy and thrombotic thrombocytopenic purpura: a systematic review, 2018-2023. Am J Hematol. 2023, 10.1002\/ajh.27104","journal-title":"Am J Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/205034-ceftriaxone-induced-thrombotic-thrombocytopenic-purpura-treated-successfully-with-plasmapheresis-and-eculizumab-a-rare-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:02Z","timestamp":1707508142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/205034-ceftriaxone-induced-thrombotic-thrombocytopenic-purpura-treated-successfully-with-plasmapheresis-and-eculizumab-a-rare-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.48898","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,16]]}}}